Extragonadal primary germ cell tumour – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:27:25 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Extragonadal primary germ cell tumour – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety of SGN-ALPV in patients with advanced solid tumors https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-of-sgn-alpv-in-patients-with-advanced-solid-tumors/ Mon, 04 May 2026 08:06:47 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-of-sgn-alpv-in-patients-with-advanced-solid-tumors/ This study aims to evaluate the safety and the best dose of a new drug called SGN-ALPV. The research focuses on patients with Advanced Solid Tumors, which are types of cancer that have spread or grown significantly in various parts of the body. The specific types of cancer being studied include Gastroesophageal Junction Carcinoma, which is cancer located where the esophagus meets the stomach, Non-small cell lung cancer, Gastric cancer, Cervical cancer, Ovarian cancer, and Endometrial cancer. The study also includes certain types of Malignant Ovarian Germ Cell Tumor, Malignant Testicular Germ Cell Tumor, and Malignant Extragonadal Germ Cell Tumor, which are cancers that arise from specific types of cells known as germ cells.

The treatment involves the intravenous administration of SGN-ALPV, meaning the medicine is delivered directly into a vein through a needle or tube. Participants in the study will receive the drug in different amounts to help researchers determine the highest dose that can be given safely without causing too many side effects. During the study, medical professionals will monitor how the body reacts to the medication and how much of the drug remains in the bloodstream over time.

]]>